ArticleScientific reports2019
The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 61 citations in OpenAlex.
- Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors.Investigational new drugs · 2025Trial
- Beyond probiotics and pathobionts: mechanistic roles of enterococcus-derived bioactive components in health and disease.Folia microbiologica · 2026Review
- Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis.Immunology · 2026Review
- Review
- Modeling Microbiome Modulation of Tumor Metabolic Networks to Predict Synergistic Therapies.bioRxiv : the preprint server for biology · 2026Article
- Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.Frontiers in oncology · 2026Review
- Review
- The gut-skin axis in melanoma: from microbial regulatory mechanisms to clinical translation for precision management.Frontiers in microbiology · 2026Review
- Live biotherapeuticGut microbes · 2025Article
- Current status and future perspectives of multi-modal bacteria-based cancer therapies.Clinical and translational medicine · 2025Review
- The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.Nature reviews. Drug discovery · 2025Review
- Gut microbiota shapes cancer immunotherapy responses.NPJ biofilms and microbiomes · 2025Review
- Microbiota mechanisms in cancer progression and therapy.Cell chemical biology · 2025Review
- Article
- Metagenomic evaluation, antimicrobial activities, and immune stimulation of probiotics from dietary supplements and dairy products.Scientific reports · 2025Article
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation.Microbiome · 2025Article
- Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients.Cell host & microbe · 2024Article
- Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.Medical oncology (Northwood, London, England) · 2024Review
- Tumor Immune Microenvironment in Gynecologic Cancers.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many links between gut microbiota and disease development have been established in recent years, with particular bacterial strains emerging as potential therapeutics rather than causative agents. In this study we describe the immunostimulatory properties of Enterococcus gallinarum MRx0518, a candidate live biotherapeutic with proven anti-tumorigenic efficacy. Here we demonstrate that strain MRx0518 elicits a strong pro-inflammatory response in key components of the innate immune system but also in intestinal epithelial cells. Using a flagellin knock-out derivative and purified recombinant protein, MRx0518 flagellin was shown to be a TLR5 and NF-κB activator in reporter cells and an inducer of IL-8 production by HT29-MTX cells. E. gallinarum flagellin proteins display a high level of sequence diversity and the flagellin produced by MRx0518 was shown to be more potent than flagellin from E. gallinarum DSM100110. Collectively, these data infer that flagellin may play a role in the therapeutic properties of E. gallinarum MRx0518.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.